Efficient tumor control by immunotherapies relies on robust CD8+ cytotoxic T lymphocyte (CTL) activity [1–3] and these immune checkpoint blocking (ICB) antibodies release the inhibitory pathways restraining the action of CTLs. Here, CD8A is linked to neoplasm.